A Peptide-Antibody Hybrid That Enters Only Tumor Cells and Escapes Their Trapping Compartments | Research

The takeaway

Engineers created a tumor-specific antibody fused with a cyclic peptide targeting EpCAM that penetrates into the cytosol of cancer cells with 2-fold improved endosomal escape, solving two major drug delivery challenges at once.

2-fold escape improvement
Engineering endosomal escape motifs into both VH and VL domains doubled cytosolic delivery efficiency while maintaining tumor cell specificity via EpCAM-targeting cyclic peptide

What the researchers found

The engineering process involved several innovations:

1. Reduced non-specific cell binding by lowering HSPG-binding activity of the parent antibody

2. Added tumor specificity by fusing a cyclic peptide recognizing EpCAM (a tumor-associated marker) to the antibody's light chain

3. Engineered endosomal escape motifs into both the heavy chain (VH) and light chain (VL) variable domains

4. The final construct, epCT65, effectively localized to the cytosol of only EpCAM-expressing tumor cells

5. Achieved approximately 2-fold improved endosomal escape efficiency compared to constructs with escape motifs in either VH or VL alone

6. Maintained full IgG format, preserving stability and potential for clinical development

Why it matters

Most cancer-targeting antibodies work by binding to the outside of cancer cells. But many important cancer targets — transcription factors, signaling proteins, protein-protein interactions — are inside the cell. This peptide-antibody hybrid addresses both the specificity problem (hitting only cancer cells) and the delivery problem (actually reaching the cell interior) in a single molecule, which could unlock an entire class of previously inaccessible intracellular cancer targets.

How the study worked

Protein engineering study using iterative antibody modification. The parent cytotransmab (TMab4-WYW) was modified to reduce non-specific binding, then fused with an EpCAM-targeting cyclic peptide. Endosomal escape motifs were engineered into both variable domains through functional grafting. Cell penetration, tumor specificity, and cytosolic localization were confirmed using fluorescence microscopy and functional assays in EpCAM-positive and EpCAM-negative cell lines.

What this study cannot tell us

All experiments were conducted in cell lines — no animal studies or human data are reported. The 2-fold improvement in endosomal escape, while significant, may still leave much of the antibody trapped in endosomes. Long-term stability and in vivo pharmacokinetics of the chimeric construct are unknown. EpCAM is expressed on some normal epithelial cells, so tumor specificity may not be absolute. No therapeutic payload was tested — only the delivery vehicle was validated.

How to read the evidence

This is a preclinical protein engineering study validated in cell lines. While the engineering achievements are impressive, no in vivo data or therapeutic payload testing is presented. This represents proof-of-concept for a drug delivery platform at the earliest stage of development.

When this study was published

Published in 2018, this study introduced the cytotransmab concept with tumor specificity. The field of intracellular antibody delivery has continued to advance, with several competing approaches now in development.

The bigger picture

Intracellular drug delivery is one of the biggest unsolved challenges in medicine. While cell-penetrating peptides can enter cells, they lack specificity. Antibodies have excellent specificity but can't reach the cytosol. This peptide-antibody fusion represents a convergence of both fields, and the full IgG format makes it compatible with existing antibody manufacturing infrastructure. If successful, this platform could transform how we deliver therapies to intracellular cancer targets.

Questions still open

Does epCT65 maintain its tumor specificity and cytosol penetration in animal tumor models?
What therapeutic payloads (toxins, siRNA, small molecules) can be effectively delivered using this cytotransmab platform?
Can the endosomal escape efficiency be further improved to approach near-complete cytosolic delivery?

Common questions

Why is getting drugs inside cancer cells so difficult?

Cells have multiple barriers to keep foreign molecules out. Even when drugs are taken up by cells, they usually get trapped in compartments called endosomes, where they're eventually destroyed. Getting a drug all the way into the cytosol — where most cancer-driving proteins operate — requires overcoming both the cell membrane barrier and escaping from endosomes. This study solves both problems with a single engineered molecule.

What is a cyclic peptide and why was it used here?

A cyclic peptide is a short amino acid chain with its ends joined in a ring, making it more stable and better at binding targets than a linear peptide. In this study, a cyclic peptide that specifically recognizes EpCAM — a protein commonly found on tumor cells — was fused to an antibody. This gave the antibody tumor specificity: it enters only cancer cells that display EpCAM, not healthy cells that lack it.

Read the original research

Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal escape efficacy.

Biochemical and biophysical research communications, 503(4), 2510-2516

View on PubMed ↗Publisher’s paper ↗

Citation

Kim, Ji-Sun; Park, Jae-Yeong; Shin, Seung-Min; Park, Seong-Wook; Jun, Sei-Yong; Hong, Jin-Sun; Choi, Dong-Ki; Kim, Yong-Sung. (2018). Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal escape efficacy.. Biochemical and biophysical research communications, 503(4), 2510-2516. https://doi.org/10.1016/j.bbrc.2018.07.008